STAT3 as novel drug target for multiple age-related disorders: docking and simulation analysis

Area of Science:

• Biochemistry
• Pharmacology
• Computational Biology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is implicated in numerous age-related disorders (ARDs) including cancer and neurodegenerative diseases.
• Inhibiting STAT3 activity presents a potential therapeutic strategy for various ARDs.
• STAT3 has emerged as a significant and promising drug target for developing novel treatments.

Purpose of the Study:

• To identify potential STAT3 dimerization inhibitors using computational methods.
• To evaluate the binding affinity and stability of identified inhibitors with STAT3.
• To propose novel lead compounds for the therapeutic treatment of multiple ARDs.

Main Methods:

• Docking-based virtual screening was employed to identify potential STAT3 inhibitors.
• Molecular dynamics simulations were conducted to assess the stability and binding interactions of lead compounds.
• Binding affinities of selected ligands with STAT3 were calculated and compared.

Main Results:

• Ligand 01 (ZINC20601870) and Ligand 02 (ZINC01216760) displayed superior binding affinities (-8.01 Kcal/mol and -6.91 Kcal/mol, respectively) compared to other screened ligands.
• Both identified ligands achieved stable equilibrium with STAT3 during molecular dynamics simulations.
• These findings highlight the potential of Ligand 01 and Ligand 02 as effective STAT3 inhibitors.

Conclusions:

• Ligand 01 and Ligand 02 are identified as promising lead compounds for STAT3 inhibition.
• Further optimization of these ligands may lead to the development of novel therapeutic agents for multiple ARDs.
• The study supports the therapeutic potential of targeting STAT3 for age-related diseases.